Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses

TY - JOUR

T1 - Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses

AU - Sørensen, Ole E.

AU - Clemmensen, Stine N

AU - Dahl, Sara L

AU - Østergaard, Ole

AU - Heegaard, Niels H H

AU - Glenthøj, Andreas

AU - Nielsen, Finn Cilius

AU - Borregaard, Niels

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Papillon-Lefèvre syndrome (PLS) results from mutations that inactivate cysteine protease cathepsin C (CTSC), which processes a variety of serine proteases considered essential for antimicrobial defense. Despite serine protease-deficient immune cell populations, PLS patients do not exhibit marked immunodeficiency. Here, we characterized a 24-year-old woman who had suffered from severe juvenile periodontal disease, but was otherwise healthy, and identified a homozygous missense mutation in CTSC indicative of PLS. Proteome analysis of patient neutrophil granules revealed that several proteins that normally localize to azurophil granules, including the major serine proteases, elastase, cathepsin G, and proteinase 3, were absent. Accordingly, neutrophils from this patient were incapable of producing neutrophil extracellular traps (NETs) in response to ROS and were unable to process endogenous cathelicidin hCAP-18 into the antibacterial peptide LL-37 in response to ionomycin. In immature myeloid cells from patient bone marrow, biosynthesis of CTSC and neutrophil serine proteases appeared normal along with initial processing and sorting to cellular storage. In contrast, these proteins were completely absent in mature neutrophils, indicating that CTSC mutation promotes protease degradation in more mature hematopoietic subsets, but does not afect protease production in progenitor cells. Together, these data indicate CTSC protects serine proteases from degradation in mature immune cells and suggest that neutrophil serine proteases are dispensable for human immunoprotection.

AB - Papillon-Lefèvre syndrome (PLS) results from mutations that inactivate cysteine protease cathepsin C (CTSC), which processes a variety of serine proteases considered essential for antimicrobial defense. Despite serine protease-deficient immune cell populations, PLS patients do not exhibit marked immunodeficiency. Here, we characterized a 24-year-old woman who had suffered from severe juvenile periodontal disease, but was otherwise healthy, and identified a homozygous missense mutation in CTSC indicative of PLS. Proteome analysis of patient neutrophil granules revealed that several proteins that normally localize to azurophil granules, including the major serine proteases, elastase, cathepsin G, and proteinase 3, were absent. Accordingly, neutrophils from this patient were incapable of producing neutrophil extracellular traps (NETs) in response to ROS and were unable to process endogenous cathelicidin hCAP-18 into the antibacterial peptide LL-37 in response to ionomycin. In immature myeloid cells from patient bone marrow, biosynthesis of CTSC and neutrophil serine proteases appeared normal along with initial processing and sorting to cellular storage. In contrast, these proteins were completely absent in mature neutrophils, indicating that CTSC mutation promotes protease degradation in more mature hematopoietic subsets, but does not afect protease production in progenitor cells. Together, these data indicate CTSC protects serine proteases from degradation in mature immune cells and suggest that neutrophil serine proteases are dispensable for human immunoprotection.

KW - Adult

KW - Antimicrobial Cationic Peptides

KW - Bone Marrow

KW - Cathepsin C

KW - Cell Separation

KW - Defensins

KW - Female

KW - Flow Cytometry

KW - Homozygote

KW - Humans

KW - Immune System

KW - Ionomycin

KW - Mutation, Missense

KW - Neutrophils

KW - Papillon-Lefevre Disease

KW - Proteome

KW - Reactive Oxygen Species

KW - Serine Proteases

KW - Subcellular Fractions

U2 - 10.1172/JCI76009

DO - 10.1172/JCI76009

M3 - Journal article

C2 - 25244098

SN - 0021-9738

VL - 124

SP - 4539

EP - 4548

JO - The Journal of Clinical Investigation

JF - The Journal of Clinical Investigation

IS - 10

ER -